NovoSeven is a recombinant factor VIIa (rfVIIa) product marketed by Novo Nordisk. NovoSeven acts as a bypassing agent for patients who have developed inhibitors against fVIII in hemophilia A and fIX in hemophilia B. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X, thereby increasing thrombin levels and formation of fibrin clots.
NovoSeven was originally developed by ZymoGenetics, which was acquired by Bristol-Myers Squibb. Novo Nordisk licensed NovoSeven from ZymoGenetics in 2000, and has marketed it globally since.
LIST OF FIGURES
9 Figure 76: Vonvendi for hemophilia – SWOT analysis
10 Figure 54: Datamonitor Healthcare’s drug assessment summary of NovoEight for hemophilia
12 Figure 55: Datamonitor Healthcare’s drug assessment summary of NovoEight for hemophilia
LIST OF TABLES
6 Table 1: NovoSeven drug profile
7 Table 2: NovoSeven pivotal trial data in hemophilia
13 Table 3: NovoSeven sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.